Lineage Cell Therapeutics (LCTX) Q3 2026 earnings review
Lineage buys a brain therapy, but its cash runway shortens
Lineage Cell Therapeutics, a developer of off-the-shelf human cell transplants, bought a clinical-stage Huntington's disease drug while its partner revenue fell and its cash timeline shortened. Collaboration revenue dropped 62% from a year ago, and operating losses nearly doubled to $7 million as research and payroll costs climbed. Chief executive Brian M. Culley paid $5 million in cash and stock for NeuroAirmid Therapeutics, pulling the company's cash runway back by one quarter to the second quarter of 2028.
| Revenue | $1.4M -61% from a year ago |
|---|---|
| Loss from operations | $7.3M $3.8M loss a year ago |
| Cash and marketable securities | $45.2M $50.8M last quarter |
| Cash runway outlook | Cut 1 quarter now into Q2 2028 (was Q3 2028) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because new clinical progress in the in-house pipeline roughly balances the shorter cash runway and a delay in the corneal eye program. Adding the Huntington's disease trial gives the biotech a human study mostly paid for by a state grant, and its diabetes program hit a three-liter manufacturing milestone with new patent protection. One caution: the corneal eye program slipped its initial animal data target from this year into early 2027, and Roche still gave no timeline for advancing the lead OpRegen eye therapy.
The question now is whether expanding the in-house pipeline creates partner-ready drugs before the $45 million cash balance runs low. Either the new Huntington's, hearing and diabetes programs deliver early data that brings in partner money, or rising manufacturing bills force more stock sales while waiting on Roche. Initial animal data from the corneal program in the first quarter of 2027 and fourth-quarter cash burn will provide the next test.
🐂 Bull Case
NeuroAirmid Deal Adds a Third Clinical Trial
"Today, we closed the acquisition of NeuroAirmid Therapeutics adding HUNT1, a third clinical-stage asset to our development pipeline," chief executive Brian M. Culley said. Lineage Cell Therapeutics develops off-the-shelf human cell transplants to replace damaged tissue, and HUNT1 is a neural stem cell treatment for Huntington's disease, a fatal brain disorder with no cure.
The California biotech bought NeuroAirmid to expand the drug pipeline it owns outright while waiting on partner Roche. Investigators at the University of California, Irvine have already dosed 6 of up to 21 patients in an ongoing Phase 1b/2a trial with no serious side effects. Because HUNT1 uses the same base cell line as Lineage's AlloSCOPE manufacturing system, the company plans to move production in-house.
- Upfront price: $4.7 million, paid roughly half in cash and half in stock
- Delayed payments: up to $5 million after one year, plus up to $48 million for clinical and regulatory goals
- Grant support: a $12 million California state grant covers most trial costs, "reducing our out-of-pocket development costs" to an estimated $3.1 million through February 2030
What to watch: safety and motor-score updates from the first four dose groups of 12 patients in the Huntington's study during 2027. Clean safety and biomarker signals would give the company a clinical catalyst it controls directly.
Diabetes Program Reaches Three-Liter Scale and Patented Status
Lineage wants to prove its AlloSCOPE 5D bioreactor manufacturing system can brew human replacement cells in bulk before spending heavily on clinical trials. In its ILT1 program for Type 1 diabetes, the cell-therapy maker previously stopped disclosing exact bioreactor sizes after passing half a liter.
This quarter it restored concrete numbers, "demonstrating the scalability of our AlloSCOPE 5D technology at 100ml, to 3 liter scale". Just as important, scientists succeeded in "differentiating pluripotent stem cells into islet cell precursors in a 5D system", meaning the bulk cells took the first step toward becoming insulin-producing tissue. The US Patent Office also issued a patent covering the 5D platform through June 2043.
What to watch: whether the biotech can turn those precursor cells into fully functional insulin-making islet cells inside the same bioreactor system over the next year. Completing that final step would make the diabetes program ready for animal testing or a partner deal.
Hearing Loss Partner Approves Second Year of Work
ReSonance is Lineage's auditory nerve cell transplant for hearing loss, funded up to $12 million over three years by partner William Demant Invest. A joint scientific committee from both firms reviewed the first year of laboratory work and approved moving the program into its second year.
The Carlsbad company finished its first clinical-grade manufacturing batch after three practice runs and set up an animal model of deafness to test whether the cells work. Both partners scheduled a fourth-quarter meeting with the Danish Medicines Agency to discuss human trial plans, showing that partner-funded work is progressing on schedule.
What to watch: the outcome of the fourth-quarter Danish regulatory meeting and initial animal hearing results in 2027. Clear regulatory advice will set the timeline for filing an application to start human trials.
🐻 Bear Case
Cash Runway Shortens while Eye Data Slips
Culley said the state grant for the new Huntington's trial let Lineage buy NeuroAirmid "without deviating meaningfully from our historic and disciplined levels of investment". Yet the company pulled back its cash runway outlook for the first time in two years, stating its $45.2 million in cash and securities is now "Expected to Support Planned Operations into Q2 2028" instead of Q3 2028.
That cuts against management's claim of minor financial impact because the acquisition adds roughly $2.4 million in upfront cash, up to $2.5 million in cash next November, $3.1 million in shared trial bills, and all future manufacturing scale-up expenses. At the same time, Culley pushed back the target for "initial preclinical data in the first quarter of 2027" on COR1, its corneal eye program, missing the prior 2026 goal after already dropping its promise to give a human trial timeline.
What to watch: fourth-quarter cash burn and stock sales under the at-the-market offering program once the upfront NeuroAirmid payment clears. If quarterly operating cash burn rises back above $6.2 million by our math, the company will either lose another quarter of runway or issue more shares.
Partner Revenue Recognition Slows to a Crawl
Lineage earns almost all of its revenue by working off upfront payments from Roche for the OpRegen eye program and from William Demant Invest for the hearing program. Collaboration revenue dropped 62% from a year ago to $1.3 million, which the release blamed on "fewer services provided in the current year".
By our math, the balance of deferred revenue—cash collected from partners that is recognized as work happens—shrank by just $256 thousand this quarter to $13.8 million, down from a $698 thousand drawdown in the second quarter and $995 thousand in the first. That slower pace shows Lineage's billable work on Roche's Phase 2a study is winding down, and makes its prior accounting estimate of recognizing most of the $13.8 million balance by December 2027 look unlikely without a schedule change.
What to watch: the remaining performance obligation schedule in Note 3 of the upcoming third-quarter 10-Q filing. An extension of the December 2027 completion date would confirm that Roche and hearing-loss collaboration work is taking longer than planned.
Risks this quarter didn't answer
Three standing risks received no new numbers or decisions in the third-quarter earnings release.
- Roche's OpRegen timeline: Genentech's Phase 2a GAlette study remains open at 17 sites testing surgical devices, with no decision on starting a controlled Phase 2/3 trial that would unlock milestone cash and speed up warrant exercises.
- Spinal cord trial enrollment and grant: the release says the DOSED study of OPC1 is enrolling without saying whether the third patient was treated or what happened to its California grant application.
- Subsidiary legal dispute: the release gives no update on minority shareholder HBL's valuation dispute over OpRegen intercompany rights, which awaits the quarterly 10-Q filing.
👓 Other Themes
Jerusalem Manufacturing Faces Active Regional War Risk
Lineage runs its cell banking and product manufacturing through its subsidiary in Jerusalem, Israel, where Genentech also operates clinical sites for the OpRegen eye study. The company warned that the "ongoing 2026 Iran War and broader Israeli regional conflict" could disrupt both trial sites and factory output, making regional security an operational risk as it takes on manufacturing for the new Huntington's program.
💲 Other KPIs
Operating loss nearly doubled from $3.8 million a year ago as revenue dropped 61% to $1.4 million and total operating expenses rose 17% to $8.7 million. Research and development spending increased $0.5 million to $3.8 million for preclinical and hearing-loss work, while administrative costs grew $0.7 million to $4.9 million on higher payroll. Headline net income of $4.2 million came entirely from a $11.9 million non-cash accounting gain on warrant liabilities.
By our math, subtracting six-month operating cash use of $15.3 million from the nine-month total of $20.9 million leaves a third-quarter cash burn of $5.6 million. That is down from $7.2 million in the second quarter and $8.1 million in the first, but above the $3.6 million burned a year ago when partner upfront cash arrived.
Weighted-average diluted shares rose 13.2% from 228.9 million a year ago after stock sales and warrant exercises during the past year. The NeuroAirmid acquisition closed after the quarter ended and will add roughly $2.4 million in new shares right away, plus up to $2.5 million in shares next November.
🔮 Guidance
Cut. The biotech expects its $45.2 million in cash and marketable securities to fund planned operations into the second quarter of 2028, one quarter shorter than the third-quarter 2028 outlook given three months ago. By our math, after subtracting the NeuroAirmid cash payments, reaching Q2 2028 allows at most $6.2 million of quarterly cash burn over the next six and a half quarters. It is the first time in eight quarters that the runway date moved backward.
Cut. Initial data from animal functional models for the COR1 corneal eye program is now planned for the first quarter of 2027, pushed out from the 2026 target stated in last quarter's report. This is the second schedule delay for the program after management did not deliver a promised human-trial timeline in the second quarter.
❓ Key Questions
How many spinal cord patients have been treated in DOSED?
Management said in August that the third patient was being evaluated for the OPC1 spinal cord study, and a California grant decision was due in the summer. The release mentioned neither number.
What will moving HUNT1 onto AlloSCOPE cost over two years?
The California state grant covers most of the ongoing Huntington's trial at UC Irvine, leaving Lineage $3.1 million through 2030. However, Lineage takes on 100% of the manufacturing transfer and scale-up bills immediately.
Will the December 2027 deferred revenue schedule be extended?
Deferred revenue shrank by only $256 thousand this quarter to $13.8 million. Recognizing that balance by December 2027 would require quarterly collaboration revenue to more than double from the current $1.3 million pace.
What caused the COR1 eye data to slip into 2027?
Lineage hit its 5D bioreactor expansion goals for COR1 but pushed initial animal model results from 2026 to the first quarter of 2027. Investors need to know when human trials can start.